NFATC2 and cardiac hypertrophy: Cardiac-specific activation of the calcineurin-NFAT pathway was sufficient to induce myocardial hypertrophy [33], whereas both pharmacological inhibition [24] and genetic deletion of NFATc2 and c3 [2, 46] alleviated pathological remodeling in animal models.